IndieBio

IndieBio accepts pre-seed companies into a four-month accelerator that provides $250,000 in initial funding alongside access to fully equipped wet-lab space in San Francisco or New York. Founders relocate to the lab and receive hands-on mentorship in company building, scientific de-risking, and fundraising. The program concludes with a Demo Day where companies present to later-stage life-science investors.

Po Bronson serves as Managing Director and leads the broader investment thesis and mentor network. Aron Jazayeri is a General Partner focused on deal selection and portfolio support. Investment decisions are collegial but ultimately sit with the IndieBio leadership team within the larger SOSV partnership structure.

IndieBio is a wholly owned accelerator program of SOSV, the multi-stage venture capital firm. SOSV provides the fund capital, back-office infrastructure, and follow-on investment capacity. IndieBio operates with its own brand, scientific advisory network, and lab facilities, but its portfolio companies go through the SOSV investment committee for any subsequent funding rounds.

IndieBio operates exclusively at the pre-seed stage. It is typically the first institutional capital into a company, often before any significant venture round. The program is designed to take a company from a scientific concept to a Series A-ready entity with proof-of-concept data, a defensible IP position, and a viable business plan.

IndieBio does not invest in traditional small-molecule drug development aimed at large chronic-disease markets, nor does it back therapeutic approaches intended to run through multi-year FDA approval processes within the fund's life. The program also avoids software-only companies; there must be a physical biology or deep-tech hardware component to the startup's approach.

IndieBio only makes direct investments into individual startups. It does not invest as a limited partner in other venture funds. The firm's capital comes from SOSV's core funds, and those SOSV vehicles are the sole investment vehicles used for IndieBio portfolio companies.

IndieBio encourages external co-investors to join its portfolio companies at or shortly after the accelerator cohort ends. Since the program's $250,000 check is typically insufficient to carry a biotech company to a full Series A, IndieBio actively syndicates follow-on rounds, often alongside domain-specialist venture firms and corporate venture arms, while SOSV may also contribute pro-rata follow-on capital.